PATENT CLAIM ANALYSIS

Application Number: 16103226
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["424", "501000"]

Abstract:
The invention provides compositions comprising microparticles wherein the microparticles comprise at least one adenosine 2 a  receptor antagonist (A2ARA), at least one pharmaceutically acceptable polymer and at least one pharmaceutically acceptable negatively charged agent wherein the microparticles optionally have a highly negative zeta potential of less than about −40 mV. The invention also provides pharmaceutical compositions of the microparticles of the invention and methods of using the compositions of the invention to enhance an immune response in a patient in need thereof and as anti-cancer immunotherapy.

Claim (Index 14):
The composition of  claim 13 , wherein the effective particle size of the microparticles is selected from 10 microns or lower, 5 microns or lower, 3 microns or lower, 2 microns or lower, 900 nm or lower, 700 nm or lower, 600 nm or lower and 500 nm or lower.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 96.0
- Lexical Diversity: 1.59649
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13878561', '09715902', '15393013', '15808534', '15458560']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7107084774457516
- 35 USC 102 Novelty (BERT): 0.5103141426401965
- Combined Prediction Score: 0.6906690439651961
- Mean Citation Score: 157.144396
- Max Citation Score: 161.34763
- Similarity Product: 83.4656498901868

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test